Knoll Capital Management, LLC - Q3 2022 holdings

$171 Million is the total value of Knoll Capital Management, LLC's 33 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 19.5% .

 Value Shares↓ Weighting
BHVN  Biohaven Pharmactl Hldg Co L$136,181,000
+3.6%
900,8440.0%79.57%
+6.1%
ALDX BuyAldeyra Therapeutics Inc$10,025,000
+67.2%
1,877,305
+24.9%
5.86%
+71.2%
ENTX  Entera Bio Ltd$2,584,000
-21.8%
2,484,2750.0%1.51%
-19.9%
ALT BuyAltimmune Inc$2,220,000
+42.7%
173,864
+30.7%
1.30%
+46.1%
 Anavex Life Sciences Corp$2,175,000
+3.1%
210,7890.0%1.27%
+5.6%
ORGS  Orgenesis, Inc.$1,869,000
-41.3%
1,316,3640.0%1.09%
-39.9%
CVS  CVS Health Corp$1,384,000
+3.0%
14,5000.0%0.81%
+5.5%
BAH  Booz Allen Hamilton HLDG CORcl a$1,200,000
+2.1%
13,0000.0%0.70%
+4.5%
TMO  Thermo Fischer Scientific Inc$1,066,000
-6.6%
2,1000.0%0.62%
-4.3%
APLT  Applied Therapeutics Inc$1,006,000
-1.9%
1,082,1230.0%0.59%
+0.3%
MO  Altria Group Inc$917,000
-3.3%
22,7000.0%0.54%
-0.9%
V  Visa$862,000
-9.7%
4,8500.0%0.50%
-7.5%
BX SellBlackstone Group LP$838,000
-42.6%
10,000
-37.5%
0.49%
-41.2%
CRBP  Corbus Pharmaceuticals HLDGS$833,000
-34.6%
5,045,8700.0%0.49%
-33.0%
GLW  Corning Inc$773,000
-7.8%
26,6000.0%0.45%
-5.4%
AEM  AGNICO EAGLE MINES LTD$650,000
-7.7%
15,3930.0%0.38%
-5.5%
MAG BuyMAG SILVER CORP$599,000
+2.6%
48,000
+177.5%
0.35%
+5.1%
EIGR SellEiger Biopharmaceuticals Inc$586,000
-86.6%
585,966
-15.6%
0.34%
-86.3%
FNV  FRANCO NEV CORP$585,000
-9.3%
4,9000.0%0.34%
-7.1%
MMX  MAVERIX METALS INC$553,000
-23.0%
165,0000.0%0.32%
-21.2%
SILV  SILVERCREST METALS INC$553,000
-35.8%
100,0000.0%0.32%
-34.2%
WPM  Wheaton Precious metals$534,000
-10.1%
16,5000.0%0.31%
-8.0%
OR  OSISKO GOLD ROYALTIES LTD$529,000
-21.7%
235,0000.0%0.31%
-19.9%
SA BuySEABRIDGE GOLD INC$487,000
+22.4%
41,000
+28.1%
0.28%
+25.6%
PAAS  PAN AMERN SILVER CORP$468,000
-44.9%
29,5000.0%0.27%
-43.7%
EQX  EQUINOX GOLD CORP$361,000
-62.8%
99,0000.0%0.21%
-61.9%
MRTX  Mirati Therapeutics, Inc$349,000
+3.9%
5,0000.0%0.20%
+6.2%
ABEO SellAbeona Therapeutics Inc$269,000
-41.6%
88,629
-96.0%
0.16%
-40.3%
BTAI  Bioxcel Therapeutics Inc$236,000
+156.5%
20,0000.0%0.14%
+160.4%
 Context Therapeutics Ins$155,000
-47.6%
139,5200.0%0.09%
-46.2%
ANVS  Annovis Bio Inc$147,000
-8.7%
14,2100.0%0.09%
-6.5%
ORMP  Oramed Pharmaceuticals Inc$130,000
+41.3%
20,0000.0%0.08%
+43.4%
SNGX SellSoligenix Inc.$15,000
-90.8%
34,766
-87.2%
0.01%
-90.3%
SPRO ExitSpero Therapeutics Inc$0-70,000
-100.0%
-0.03%
ANGN ExitAngion BioMedica Corp$0-60,000
-100.0%
-0.04%
AGTC ExitApplied Genetic Technologies$0-100,000
-100.0%
-0.04%
ASML ExitASML Holdings$0-1,280
-100.0%
-0.35%
AMD ExitAdvanced Micro Devices Inc$0-8,200
-100.0%
-0.36%
OSK ExitOSHKOSH CORP$0-8,450
-100.0%
-0.40%
LUMN ExitLumen Technologies Inc$0-100,000
-100.0%
-0.62%
ANET ExitArista Networks Inc$0-13,800
-100.0%
-0.74%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Aldeyra Therapeutics Inc35Q3 202331.6%
Corbus Pharmaceuticals HLDGS30Q3 202246.5%
Abeona Therapeutics Inc30Q3 202234.8%
Biohaven Pharmactl Hldg Co L26Q3 202379.6%
Entera Bio Ltd22Q3 20237.8%
Ampio Pharmaceuticals Inc.21Q2 201811.0%
Soligenix Inc.20Q3 20221.7%
Eiger Biopharmaceuticals Inc19Q3 20225.8%
Applied Therapeutics Inc18Q3 202319.7%
Alcobra Ltd18Q3 20176.5%

View Knoll Capital Management, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Knoll Capital Management, LLC Q3 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
HOOKIPA Pharma Inc.June 20, 20235,517,3856.8%
Applied Therapeutics Inc.January 23, 20233,450,0007.2%
Orgenesis Inc.August 14, 20201,316,3645.9%
Corbus Pharmaceuticals Holdings, Inc.February 14, 20205,045,8707.1%
ABEONA THERAPEUTICS INC.February 14, 20182,359,7675.0%
SOLIGENIX, INC.November 13, 2017870,0009.9%
ABEONA THERAPEUTICS INC.February 14, 20172,359,7675.9%
ALCOBRA LTD.February 14, 20171,205,4984.4%
Ampio Pharmaceuticals, Inc.February 14, 20172,738,3224.8%
RITTER PHARMACEUTICALS INCFebruary 14, 2017952,4348.2%

View Knoll Capital Management, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-01-16
13F-HR2023-11-14
SC 13G2023-10-04
13F-HR2023-08-15
SC 13G2023-06-20
13F-HR2023-05-15
13F-HR2023-02-14
SC 13G2023-01-23
13F-HR2022-11-14

View Knoll Capital Management, LLC's complete filings history.

Compare quarters

Export Knoll Capital Management, LLC's holdings